Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues

Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues

A combination of anti–CTLA-4 plus anti–PD-1/PD-L1 is the most effective cancer immunotherapy but causes high incidence of immune-related adverse events (irAEs). Here we report that targeting of HIF-1α suppressed PD-L1 expression on tumor cells and tumor-infiltrating myeloid cells, but unexpectedly i...

Full description

Bibliographic Details
Main Authors: Christopher M. Bailey, Yan Liu, Mingyue Liu, Xuexiang Du, Martin Devenport, Pan Zheng, Yang Liu, Yin Wang
Format: Article
Language:English
Published: American Society for Clinical Investigation 2022-05-01
Series:The Journal of Clinical Investigation
Subjects:
Therapeutics
Online Access:https://doi.org/10.1172/JCI150846

Internet

https://doi.org/10.1172/JCI150846

Similar Items